Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 38, Issue 5-6, 2000, Pages 521-532

  Itoh, Kuniaki ^a   Ohtsu, Tomoko ^a   Sasaki, Yasutsuna ^a   Ogura, Michinori ^b   Morishima, Yasuo ^b   Kasai, Masaharu ^c   Chou, Takaaki ^d   Yoshida, Kouki ^e   Ohno, Tatsuharu ^f   Mizorogi, Fumi ^g   Uike, Naokuni ^h   Sai, Toshiaki ⁱ   Taniwaki, Masafumi ^j   Ikeda, Shuichi ^k   Tobinai, Kensei ^l  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c SAPPORO HOKUYU HOSPITAL   (Japan)

^d NIIGATA CANCER CENTER HOSPITAL   (Japan)

^e HOKKAIDO CANCER CENTER   (Japan)

^f OTSU RED CROSS HOSPITAL   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h National Hospital Organization   (Japan)

ⁱ Iwaki Kyoritsu General Hospital   (Japan)

^j KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k Sasebo Shiritsu Sogo Hospital   (Japan)

^l NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

CD34+ cells; CHOP; G CSF; Lenograstim; Non Hodgkin's lymphoma

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; AUTOTRANSPLANTATION; CARDIOTOXICITY; CELL MOTILITY; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; KINETICS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 0033860862     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009059271     Document Type: Review

References (38)

1. Armitage J. (1993) Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023-1030.
2. Montserrat E., Garcia-Conde J., Vinolas N., Lopez-Guillermo A., Hernandez-Nieto L., Zubzarreta A., Maldonado J., Alacala A., Faura M. V. Llorente A., Bladé J., Fontanillas M. and Estapé J. (1996) CHOP vs ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish cooperative group for the study of hematological malignancies treatment, Spanish society of hematology). European Journal of Haematology, 57, 377-383.
3. Gordon L. I., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G. D., Barcos M., Gottlieb A. and O'Connell M. (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New England Journal of Medicine, 327, 1342-1349.
4. Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Click J. H., Coltman C. A. and Miller T. P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
5. Cooper I. A., Wolf M. M., Robertson T. I., Fox R. M., Matthews J. P., Stone J. M., Ding J. C., Dart G., Matthews J., Firkin F. C., Lowenthal R. M. and Ironside P. (1994) Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 12, 769-778.
6. The international non-Hodgkin's lymphoma prognostic factors project: (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
7. Philip T., Guglielmi C., Hagenbeek A., Somers R., Lelie H. V. D., Bron D., Sonneveld P., Gisselhrecht C., Cahn J. Y., Harousseau J. L., Coiffier B., Biron P., Mandelli F. and Chauvin F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540-1545.
8. Gianni A. M., Bregni M., Siena S., Brambilla C., Nicola M. D., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P. and Bonadonna G. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine, 336, 1290-1297.
9. Haioun C., Lepage E., Gisselbrecht C., Bastion Y., Coiffier B., Brice P., Bosly A., Dupriez B., Nouvel C., Tilly H., Lederlin P., Biron P., Brière J., Gaulard P. and Reyes F. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH 87-2. Journal of Clinical Oncology, 15, 1131-1137.
10. Santini G., Salvagno L., Leoni P., Chisesi T., Souza C. D., Sertoli M. R., Rubagotti A., Congiu A. M., Centurioni R., Olivieri A., Tedeschi L., Vespignoni M., Nati S., Soracco M., Porcellini A., Contu A., Guarnaccia C., Pescosta N., Majolino I., Spriano M., Vimercati R., Rossi E., Zambaldi G., Mangoni L., Endrizzi L., Sileni V. C., Miggiano M. C., Marino G., Damasio E. and Rizzoli V. (1998) VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. Journal of Clinical Oncology, 16, 2796-2802.
11. Shipp M. A., Abeloff M. D., Antman K. H., Carroll G., Hagenbeek A., Loeffler M., Montserrat E., Radford J. A., Salles G., Schmitz N., Symann M., Armitage J. O., Philip T. and Coiffier B. (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the Jury. Journal of Clinical Oncology, 17, 423-429.
12. Schmitz N., Linch D. C., Dreger P., Goldstone A. H., Boogaerts M. A., Ferrant A., Demuynck H. M. S., Link H., Zander A., Barge A. and Borkett K. (1996) Randomised trial of filograstim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet, 347, 353-357.
13. Vose J. M., Sharp J. G., Chan W., Nichols C., Loh K., Inwards D., Rifkin R., Matous J., Lynch J. C., Anderson J., Bierman P. J., Kessinger A. and Armitage J. O. (1997) High-dose chemotherapy (HDC) and autotransplant for non-Hodgkin's lymphoma (NHL): randomized trial of peripheral blood (PSCT) versus bone marrow (ABMT) and evaluation of minimal residual diseases (MRD). Proceedings of American Society of Clinical Oncology, 16, 90a.
14. Hartmann O., Corroller A. G. L., Blaise D., Michon L., Philip I., Norol F., Janvier M., Pico J. L., Baranzelli M. C., Rubie H., Coze C., Pinna A., Méresse V. and Benhamou E. (1997) Peripheral blood stem cell and hone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial. Annals of Internal Medicine, 126, 600-607.
15. Weaver C. H., Hazelton B., Birch R., Palmer P., Allen C., Schwartzberg L. and West W. (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 86, 3961-3969.
16. Schots R., Van Riet I., Damiaens S., Flament J., Lacor P., Staelens Y., Steenssens L., van Camp B. and De Waele M. (1996) The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can he collected by apheresis. Bone Marrow Transplantation, 17, 509-515.
17. Armitage S., Hargreaves R., Samson D., Brennan M., Kanfer E. and Navarrete C. (1997) CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplantation, 20, 587-591.
18. Haas R., Möhle R., Frühauf S., Goldschumidt H., Witt B., Flentje M., Wannenmacher M. and Hunstein W. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood, 83, 3787-3794.
19. Dreger P., Klöss M., Peterson B., Haferlach T., Löffler H., Loeffler M. and Schmitz N. (1995) Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determine yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood, 86, 3970-3978.
20. Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lillehy K., Gooley T., Demirer T., Schiffman K., Weaver C., Clift R., Chauncey T., Klarnet J., Montgomery P., Petersdorf S., Weiden P., Witherspoon R. and Buckner C. D. (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology, 13, 2547-2555.
21. Watts M. J., Sullivan A. M., Jamieson E., Pearce R., Fielding A., Devereux S., Goldstone A. H. and Linch D. C. (1997) Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting tor these parameters in 101 pretreated patients with malignant lymphoma. Journal of Clinical Oncology, 15, 535-546.
22. Moskowitz C. H., Glassman J. R., Wuest D., Maslak P., Reich L., Gucciardo A., Coady-Lyons N., Zelenetz A. D. and Nimer S. D. (1998) Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clinicat Cancer Research, 4, 311-316.
23. Freedman A., Neuberg D., Mauch P., Gribben J., Soiffer R., Anderson K., Robertson M., Fisher D. C., Schlossman R., Kroon M., Rhuda C., Kuhlman C., Ritz J. and Nadler L. (1997) Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyle colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood, 90, 4996-5001.
24. The non-Hodgkin's lymphoma pathologic classification project: (1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer, 42, 2112-2135.
25. Tobinai K., Kohno A., Shimada Y., Watanabe T., Tamura T., Takeyama K., Narabayashi M., Fukutomi T., Kondo H., Shimoyama M. and Suemasu K. (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology, 23, 250-257.
26. Ohtsu T., Wakita H., Igarashi T., Itoh K., Fujii H., Minami H. and Sasaki Y. (1997) A phase I-II study of CHOP with or without prophylactic G-CSF for aggressive non-Hodgkin's lymphoma. Proceedings of American Society of Clinical Oncology, 16, 20a.
27. Narabayashi M., Takeyama K., Fukutomi T., Tokuda Y., Tajima T., Okumura A., Chou T., Sano M., Makino H., Igarashi T., Sasaki Y., Imoto S., Ogura M., Morishima Y., Murai H., Okamoto S., Ikeda T., Kasai M., Yokozawa T. and Tobinai K. (1999) A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Japanese Journal of Clinical Oncology, 29, 285-290.
28. Knudsen L. M., Gaarsdal E., Jensen L., Nielsen K. J., Nikolaisen K. and Johnsen H. E. (1996) Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. Journal of Hematotherapy, 5, 399-406.
29. Kotasek D., Shepherd K. M., Sage R. E., Dale B. M., Norman J. E., Charles P., Gregg A., Pillow A. and Bolton A. (1992) Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplantation, 9, 11-17.
30. Pettengell R., Testa N. G., Swindell R., Crowther D. and Dexter T. M. (1993) Transplantation potential of hematopoietic cells relapsed into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood, 82, 2239-2248.
31. Bolwell B. J., Fishleder A., Andresen S. W., Lichtin A. E., Koo A., Yanssens T., Burwell R., Baucco P. and Green R. (1993) G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplantation, 12, 609-614.
32. Pettengell R., Morgenstern G. R., Woll P. J., Chang J., Rowlands M., Young R., Radford J. A., Scarffe J. H., Testa N. G. and Crowther D. (1993) Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood, 82, 3770-3777.
33. Kohno A., Takeyama K., Narabayashi M., Okamoto R., Adachi I., Tobinai K. and Shimoyama M. (1995) Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplantation, 15, 49-54.
34. 2) after salvage chemotherapy for lymphoma. Bone Marrow Transplantation, 20, 855-858.
35. Shipp M. A., Neuberg D., Janicek M., Canellos G. P. and Shulman L. N. (1995) High-dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. Journal of Clinical Oncology, 13, 2916-2923.
36. Santoro A., Balzarotti M., Tondini C., Zanini M., Giardini R., Latteri F., Rampinelli I. and Bufalino R. (1999) Dose-escalation of CHOP in non-Hodgkin's lymphoma. Annals of Oncology, 10, 519-525.
37. Lopez M., Lemoine F. M., Fouillard H., Laporte J. P., Lesage S., Isnard F., Sachowiak J., Ferrer-Le Coeur F., Morel P., Najman A., Douay L. and Gorin N. C. (1997) Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: Different levels of tumor cell reduction. Implications for autografting. Blood, 90, 283-2838.
38. Niitsu N., Iki S., Muroi K., Motomura S., Murakami M., Takeyama H., Ohsaka A. and Urabe A. (1997) Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96. British Journal of Cancer, 76, 1661-1666.